CTU Bern (Clinical Trials Unit)

First IICT call by the SNSF: Three approved projects at the Inselspital Bern

22.07.16 - In August, the SNSF has launched the first call for independent, Investigator Initiated Clinical Trials (IICTs). With the IICT programme, the SNSF aims to promote clinical studies in areas that are not in the industry focus and therefore under-researched (e.g. rare diseases, paediatric diseases, therapy combinations, dosage reduction studies and rehabilitation measures).

The call has attracted wide interest among the clinical researchers in Switzerland and a total of 75 applications have been submitted to the SNSF. Of all the applications, nine have been approved. The clinical studies will be allocated a total of 12.6 million francs. Most of them will last between four and five years and involve 100 to 400 patients in 14 study centres.
 
With three approved applications, the clinical researchers at the Inselspital Bern have been highly successful. CTU Bern congratulates the successful research teams:
 
Claudio L. Basseti, Department of Neurology, Inselspital Bern:
Early Sleep Apnea Treatment in Stroke: A Randomized, Rater-Blinded, Clinical Trial of Adaptive Servo-Ventilation
 
Daniel Guido Fuster, Division of Nephrology, Inselspital Bern:
NOSTONE Trial - Randomized double-blind placebo-controlled trial assessing the efficacy of standard and low dose hydrochlorothiazide treatment in the prevention of recurrent calcium nephrolithiasis
This study plans to assess the efficacy of standard and low dose hydrochlorothiazide (HCTZ) treatment in the recurrence prevention of calcium containing kidney stones. More specifically the aim is to assess the dose-response relationship for three different dosages of HCTZ.
 
Markus Schwerzmann, Department of Cardiology, Inselspital Bern:
SERVE Trial - Effect of phosphodiesterase-5 inhibition with Tadalafil on SystEmic Right VEntricular function – a multi-center, double-blind, randomized, placebo-controlled clinical trial
This study assesses the effect of phosphodiesterase (PDE)-5 inhibition with Tadalafil (Adcirca®, manufacturer Eli Lilly) on the right ventricle (RV) function, exercise capacity and neurohumoral activation in adults with a systemic RV over a 3-year follow-up period.
 
CTU Bern collaborates closely with the division of nephrology and the department of cardiology and will actively support the study teams during the planning and conduct phase of their clinical trials.
A second IICT call will be launched by the SNSF in August 2016.

 

Source & further information: